Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Receivables (2017 - 2025)

Sutro Biopharma (STRO) has disclosed Receivables for 9 consecutive years, with $4.0 million as the latest value for Q4 2025.

  • Quarterly Receivables fell 53.84% to $4.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Dec 2025, down 53.84% year-over-year, with the annual reading at $4.0 million for FY2025, 53.84% down from the prior year.
  • Receivables hit $4.0 million in Q4 2025 for Sutro Biopharma, up from $3.9 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $97.7 million in Q2 2022 to a low of $3.9 million in Q3 2025.
  • Historically, Receivables has averaged $16.2 million across 5 years, with a median of $9.9 million in 2023.
  • Biggest five-year swings in Receivables: soared 966.28% in 2022 and later plummeted 89.76% in 2023.
  • Year by year, Receivables stood at $12.5 million in 2021, then tumbled by 42.81% to $7.1 million in 2022, then surged by 406.57% to $36.1 million in 2023, then plummeted by 76.12% to $8.6 million in 2024, then crashed by 53.84% to $4.0 million in 2025.
  • Business Quant data shows Receivables for STRO at $4.0 million in Q4 2025, $3.9 million in Q3 2025, and $8.0 million in Q2 2025.